TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03454971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MinOS protocol
Description: At Day 1, Cycle 1 and 2 of the patient's oral therapy :~* Consultation with a hospital pharmacist~* Consultation with a nurse care coordinator~* Consultation with the patient's oncologist/hematologist~During this multidisciplinary consultation, will be reviewed :~* potential medical interactions,~* possible adverse effects of therapy,~* information on the prescribed drug,~* informations on the patient's lifestyle, ...~At day 8 and 15, cycle 1 and 2 :~Phone call from the nurse care coordinator during which will be reported the adverse effects and adherence issues. If needed, the nurse care coordinator can provide complementary information about the treatment.~The MINOS protocol follow up will end with a consultation with the patient's oncologist/hematologist, at day 1 cycle 3.
Study: NCT01569828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696A
Description: once daily administration of 400 mg LCZ696 for 5 days
Study: NCT03726255

Intervention type: PROCEDURE
Intervention: Mesenchymal Stem Cell injection
Description: curettage, closure of the internal opening (IO) and cell injection in IO (50%) and fistula tract (50%)
Study: NCT03827213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: A shot of long acting local anesthetic for post operative pain management

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling Interscalene Catheter
Description: ropivacaine, given through a catheter inserted between the shoulders
Study: NCT00686036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: 300 mg orally, once daily for up to 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02386410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group parent training for anxious parents

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet delivered parent training for anxious parents
Study: NCT02435979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand therapy
Description: Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hand therapy
Description: Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proximal Strengthening
Description: Patients will perform a standardized proximal strengthening protocol consisting of cervical, periscapular, and shoulder strengthening exercises. Depending on the pace and guidance needed for these exercises 25-30 minutes will be spent on proximal strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase.
Study: NCT04118231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Group 1: Dry needling Group 2: static stretching Group 3: IASTM
Study: NCT02202018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active KT intervention
Description: 1. Provider \& patient-directed infographics educating patients about home dialysis will be displayed in prominent clinic wall space~2. Educational white board presentations promoting home dialysis~3. Each clinic will receive reports outlining their current use of home dialysis in incident ESRD patients compared with provincial \& national averages~4. A Canadian version of the MATCH D tool will be provided to clinic staff, to help evaluate patient appropriateness for home dialysis.~5. Each clinic will receive an in-person visit from one of the study investigators/collaborators detailing the benefits of home dialysis, and the educational tools being offered to support care within their clinic.
Study: NCT02363582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: formula
Description: An infant formula contains prebiotics and lactoferrin
Study: NCT03405285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected Catheter
Description: The Connected Catheter is a fully internal, urethral-indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The CoCath is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
Study: NCT01006707

Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron
Description: In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.

Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron
Description: In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
Study: NCT03211156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin is an aminopenicillin antibiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00679523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690 Solution, 5.0%
Description: Once daily application for 180 days
Study: NCT03726255

Intervention type: PROCEDURE
Intervention: Mesenchymal Stem Cell injection
Description: curettage, closure of the internal opening (IO) and cell injection in IO (50%) and fistula tract (50%)

Intervention type: PROCEDURE
Intervention: Mesenchymal Stem Cell injection
Description: curettage, closure of the internal opening (IO) and cell injection in IO (50%) and fistula tract (50%)
Study: NCT03581812

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention snack 1
Description: To be eaten instead of regular snacks twice a day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention snack 2
Description: To be eaten instead of regular snacks twice a day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control snack
Description: To be eaten instead of regular snacks twice a day for 4 weeks.
Study: NCT04584229

Intervention type: OTHER
Intervention: Intervention
Description: Intervention: comprehensive individual or collective interview, recorded and transcribed
Study: NCT03381768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L2 peptide
Description: 100 ug PD-L2 peptide dissolved in DMSO and water mixed with 500ul montanide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L2 and PD-L1 peptide
Description: 100 ug PD-L2 peptide and 100ug PD-L1 peptide dissolved in DMSO and water mixed with 500ul montanide.
Study: NCT04000295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Subjects receive Apatinib orally, Dosage form: tablet, Strength: 375 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Subjects receive Etoposide capsule orally, d1-14, q3w, Dosage form: capsule, Strength: 50 mg/d
Study: NCT03205956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.~Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above.
Study: NCT01600456

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure (PE)
Description: PE will include 10 weekly sessions of individual cognitive behavioral therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure (PE)
Description: PE will include 10 weekly sessions of individual cognitive behavioral therapy.
Study: NCT04000295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, q3w, Dosage form: injectable, Strength: 80 mg/m2
Study: NCT01600456

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure (PE)
Description: PE will include 10 weekly sessions of individual cognitive behavioral therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure (PE)
Description: PE will include 10 weekly sessions of individual cognitive behavioral therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PE plus Sertraline
Description: PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PE plus Sertraline
Description: PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.
Study: NCT04072094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Locking Plate Fixation
Description: Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary Nail Fixation
Description: Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
Study: NCT04512066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889450
Description: Participants will receive oral RO6889450 QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889450
Description: Participants will receive oral RO6889450 QD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral placebo QD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Participants will receive oral risperidone QD.
Study: NCT02883062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT01224093

Intervention type: DRUG
Intervention: Chemotherapy
Description: as prescribed

Intervention type: DRUG
Intervention: Chemotherapy
Description: as prescribed

Intervention type: DRUG
Intervention: rituximab [MabThera/Rituxan]
Description: as prescribed

Intervention type: DRUG
Intervention: rituximab [MabThera/Rituxan]
Description: as prescribed
Study: NCT03661242

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Patients in shared care arm has regular combined visits with Oncologist and Clincal Exercise Physiologist (CEP). Individual physical activity plan developed by CEP for patients in shared care arm.
Study: NCT03625466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: FDC tablets or granules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: FDC granules for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to LUM/IVA for oral administration.
Study: NCT03764397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation for behavioural change
Description: The 4-week prehabilitation educational programme will consist of a meeting for one session (approximately 1 - 1.5 hours) per week. This behavioural change programme will involve a mixture of interactive and didactic sessions, facilitated by a physiotherapist, psychologists, and other health professionals. The purpose of the initial prehabilitation programme is to gain participant 'buy-in' to the programme, to assist participants engage with exercise, to help participants overcome barriers to exercise and improve self-efficacy for exercise. The prehabilitation phase will also enable participants to understand why and how to perform gentle self-paced exercise. After the prehabilitation programme, participants will be advised to engage in a 6-week gentle self-paced walking programme; i.e., a simple pedometer-driven walking programme with weekly telephone support.
Study: NCT02737943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Description: is a registered USA patented formulation since 1995. MEBO is pure herbal, natural in origin, containing beta-sitosterol phellodendron amurense, scutellaria baicalensis, coptis chinensis, pheretima aspergillum, Beeswax and sesame oil. 15, 19 The pharmacological effects are attributable to: beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensis, Beeswax and sesame oil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zagazig
Description: Standard care is an antibiotic ointment in combination of analgesic for relief of pain.
Study: NCT01665625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional interventional chemotherapy group
Description: The patients in experimental group were monitored by X-ray imaging. A 0.038 super-sliding guide wire was inserted after successful puncture, and when site of the pancreatic carcinoma was reconfirmed by conventional angiography, a 5F cobra catheter was used to place the port-catheter drug delivery system in the celiac artery (pancreatic head) or the hepatic artery (pancreatic body and tail). Finally, the port-catheter was embedded under the left upper chest.
Study: NCT00713258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid hormone (PTH) (1-84)
Description: 100 µg PTH(1-84) daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70 mg alendronate weekly
Study: NCT04550689

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone graft
Description: Bone grafts produced by Straumann LLC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone graft
Description: Bone grafts produced by Straumann LLC
Study: NCT03383640

Intervention type: OTHER
Group type: OTHER
Intervention: Active exercises
Description: Active flexion movements every waking hour of the replanted digits
Study: NCT03017378

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TB/FLU-01L
Description: TB / FLU-01L (intranasal application)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TB/FLU-01L
Description: TB/FLU-01L (sublingual application)
Study: NCT00478803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remodeling procedure associated with a subvalvular aortic ring or double sub and supra-valvular aortic annuloplasty
Description: Remodeling procedure associated with a subvalvular aortic ring: a) Five U stitches are placed inside out in the subvalvular plane (3 stitches 2 mm below the nadir of insertion of each cusp, 2 stitches below 2 of the 3 commissures at the base of the interleaflet triangles (no suture is placed at the base of the interleaflet triangle situated between the right and noncoronary sinuses to avoid injury of the bundle of His)); b) remodeling of the aortic root by scalloping a bulged graft (Gelweave ValsalvaTM); c) The 5 anchoring U stitches are passed through the inner aspect of the prosthetic aortic ring and tied down externally in the subvalvular position; d) anastomosis of the coronary ostia and to distal ascending aorta.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
Description: Expansible Prosthetic Aortic Ring: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
Study: NCT01455532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR240550-BSI-201)
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR240550-BSI-201)
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR240550-BSI-201)
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR240550-BSI-201)
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placlitaxel
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study: NCT01814696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedSentry System
Description: Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
Study: NCT02995174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dichoptic video game in an i-Pod touch device
Description: Amblyope will wear a pair of red green goggles and play the video game with 'contrast-balanced' images displayed on the screen of an i-Pod touch device. The eye with weaker eyesight will see the image with high contrast, and the good eye will see the image with low contrast. The subject will play the game one hour per day for 6 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Video game in an i-Pod touch device
Description: Amblyope will wear a pair of red green goggles and play the video game with equal contrast images displayed on the screen of an i-Pod touch device. Both eyes will see the image of same contrast. The subject will play the game one hour per day for 6 weeks.
Study: NCT04736277

Intervention type: OTHER
Intervention: Preoperative HbA1c
Description: Documentation of the preopetative HbA1c in patients undergoing noncardiac surgery under general anesthesia
Study: NCT03508726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Phase 1 dose escalation:~75gm IV three times a week~Phase II portion:~75gm IV three times a week if no dose limiting toxicities are experienced in the Phase I portion. Otherwise, ascorbate dose will be deescalated to 62.5 gm IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Phase 1 dose escalation:~75gm IV three times a week~Phase II portion:~75gm IV three times a week if no dose limiting toxicities are experienced in the Phase I portion. Otherwise, ascorbate dose will be deescalated to 62.5 gm IV
Study: NCT04010747

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing for Loved Ones (MILO)
Description: 4 sessions of behavioral coaching in motivational interviewing communication techniques

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing for Loved Ones (MILO)
Description: 4 sessions of behavioral coaching in motivational interviewing communication techniques

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Health Services Consultation and Waitlist
Description: 1 session of individualized consultation on relevant mental health services for the IP and participating PCSO and 6 weeks on a waitlist, followed by opportunity to participate in MILO sessions.
Study: NCT03928899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New procedure
Description: An optimal management on the timing and mode of delivery of pregnant women with GDM, by a comprehensive assessment and consideration of their fetal weight, gestational age, and cervical ripeness.
Study: NCT00650247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan Succinate Tablets 100 mg
Description: 100mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex® Tablets 100 mg
Description: 100mg, single dose fed
Study: NCT00030667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02647723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: 2 dietary supplement gel capsules providing 450 mg of DHA twice daily by oral intake for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 2 dietary supplement gel capsules providing 450 mg of soybean oil twice daily by oral intake for 24 weeks
Study: NCT04150796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral Hernia Repair
Description: Participants will undergo robotic ventral hernia repair according to the assigned treatment arm.